- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This volume deals with the consequences of activation of peripheral dopamine receptors impacting on the cardiovascular system, either the prejunctional neuroinhibitory dopamine receptor or the postjunctional dopamine receptor. It is useful for cardiovascular clinicians and receptor specialists.
Andere Kunden interessierten sich auch für
- A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics147,99 €
- Receptors and Other Targets for Toxic Substances79,99 €
- Therapeutic Applications of Dopamine D3 Receptor Function110,99 €
- Current Antipsychotics220,99 €
- Therapeutic Applications of Dopamine D3 Receptor Function110,99 €
- A.V. Valdman (ed.)Drug Dependence and Emotional Behavior109,99 €
- Timothy S GaginellaSerotonin and Gastrointestinal Function439,99 €
-
-
-
This volume deals with the consequences of activation of peripheral dopamine receptors impacting on the cardiovascular system, either the prejunctional neuroinhibitory dopamine receptor or the postjunctional dopamine receptor. It is useful for cardiovascular clinicians and receptor specialists.
Produktdetails
- Produktdetails
- Verlag: Taylor & Francis
- Seitenzahl: 384
- Erscheinungstermin: 28. September 1989
- Englisch
- Abmessung: 233mm x 159mm x 23mm
- Gewicht: 653g
- ISBN-13: 9780824781002
- ISBN-10: 0824781007
- Artikelnr.: 22013348
- Verlag: Taylor & Francis
- Seitenzahl: 384
- Erscheinungstermin: 28. September 1989
- Englisch
- Abmessung: 233mm x 159mm x 23mm
- Gewicht: 653g
- ISBN-13: 9780824781002
- ISBN-10: 0824781007
- Artikelnr.: 22013348
Paul Hieble
Part I: Characterization of Peripheral Dopamine Receptors 1. Functional
Models for and Characteristics of DA1 and DA2 Dopamine Receptors in the
Periphery 2. Affinities of Dopamine Agonists and Antagonists for Peripheral
Dopamine Receptors Part II: Inhibition of Sympathetic Neurotransmission by
Dopaminergic Agonists 3. Effect of Rigid and Nonrigid Analogs of Dopamine
on Vascular Neurotransmission 4. Inhibition of Cardiac Neurotransmission In
Vivo and In Vitro by Structural Analogs of Dopamine 5. Cardiac and Vascular
Consequences of Modulation of Sympathetic Neurotransmission by Dopamine
Receptor Agonists Part III: Cardiovascular Effects of Selective Dopamine
Receptor Agonists in Experimental Animals 6. The Pentobarbital-Anesthesized
Rat: Cardiovascular Mechanisms of Action of DA1 and DA2 Receptor Agonists
7. Correlation of Dopamine Receptor Selectivity and Hemodynamic Effects on
the Intact Animal 8. Peripheral Dopaminergic Agonist Activity of
Aminoethylindolones and Related Compounds 9. Cardiovascular Activity of
Ergoline Derivatives 10. Inhibition of Dopamine ß-Hydroxylase to Increase
Dopaminergic Tone In Vivo Part IV: Dopamine Receptors in Man: Therapeutic
Applications 11. Clinical Utility of Cardiovascular Agents Acting on the
Dopamine Receptor 12. Dopaminergic Control of Aldosterone Secretion 13.
Hemodynamic Activity of N-n -propyl-N-n -Butyldopamine 14. Clinical Effects
of Fenoldopam, a Potent Dopamine (DA1) Agonist
Models for and Characteristics of DA1 and DA2 Dopamine Receptors in the
Periphery 2. Affinities of Dopamine Agonists and Antagonists for Peripheral
Dopamine Receptors Part II: Inhibition of Sympathetic Neurotransmission by
Dopaminergic Agonists 3. Effect of Rigid and Nonrigid Analogs of Dopamine
on Vascular Neurotransmission 4. Inhibition of Cardiac Neurotransmission In
Vivo and In Vitro by Structural Analogs of Dopamine 5. Cardiac and Vascular
Consequences of Modulation of Sympathetic Neurotransmission by Dopamine
Receptor Agonists Part III: Cardiovascular Effects of Selective Dopamine
Receptor Agonists in Experimental Animals 6. The Pentobarbital-Anesthesized
Rat: Cardiovascular Mechanisms of Action of DA1 and DA2 Receptor Agonists
7. Correlation of Dopamine Receptor Selectivity and Hemodynamic Effects on
the Intact Animal 8. Peripheral Dopaminergic Agonist Activity of
Aminoethylindolones and Related Compounds 9. Cardiovascular Activity of
Ergoline Derivatives 10. Inhibition of Dopamine ß-Hydroxylase to Increase
Dopaminergic Tone In Vivo Part IV: Dopamine Receptors in Man: Therapeutic
Applications 11. Clinical Utility of Cardiovascular Agents Acting on the
Dopamine Receptor 12. Dopaminergic Control of Aldosterone Secretion 13.
Hemodynamic Activity of N-n -propyl-N-n -Butyldopamine 14. Clinical Effects
of Fenoldopam, a Potent Dopamine (DA1) Agonist
Part I: Characterization of Peripheral Dopamine Receptors 1. Functional
Models for and Characteristics of DA1 and DA2 Dopamine Receptors in the
Periphery 2. Affinities of Dopamine Agonists and Antagonists for Peripheral
Dopamine Receptors Part II: Inhibition of Sympathetic Neurotransmission by
Dopaminergic Agonists 3. Effect of Rigid and Nonrigid Analogs of Dopamine
on Vascular Neurotransmission 4. Inhibition of Cardiac Neurotransmission In
Vivo and In Vitro by Structural Analogs of Dopamine 5. Cardiac and Vascular
Consequences of Modulation of Sympathetic Neurotransmission by Dopamine
Receptor Agonists Part III: Cardiovascular Effects of Selective Dopamine
Receptor Agonists in Experimental Animals 6. The Pentobarbital-Anesthesized
Rat: Cardiovascular Mechanisms of Action of DA1 and DA2 Receptor Agonists
7. Correlation of Dopamine Receptor Selectivity and Hemodynamic Effects on
the Intact Animal 8. Peripheral Dopaminergic Agonist Activity of
Aminoethylindolones and Related Compounds 9. Cardiovascular Activity of
Ergoline Derivatives 10. Inhibition of Dopamine ß-Hydroxylase to Increase
Dopaminergic Tone In Vivo Part IV: Dopamine Receptors in Man: Therapeutic
Applications 11. Clinical Utility of Cardiovascular Agents Acting on the
Dopamine Receptor 12. Dopaminergic Control of Aldosterone Secretion 13.
Hemodynamic Activity of N-n -propyl-N-n -Butyldopamine 14. Clinical Effects
of Fenoldopam, a Potent Dopamine (DA1) Agonist
Models for and Characteristics of DA1 and DA2 Dopamine Receptors in the
Periphery 2. Affinities of Dopamine Agonists and Antagonists for Peripheral
Dopamine Receptors Part II: Inhibition of Sympathetic Neurotransmission by
Dopaminergic Agonists 3. Effect of Rigid and Nonrigid Analogs of Dopamine
on Vascular Neurotransmission 4. Inhibition of Cardiac Neurotransmission In
Vivo and In Vitro by Structural Analogs of Dopamine 5. Cardiac and Vascular
Consequences of Modulation of Sympathetic Neurotransmission by Dopamine
Receptor Agonists Part III: Cardiovascular Effects of Selective Dopamine
Receptor Agonists in Experimental Animals 6. The Pentobarbital-Anesthesized
Rat: Cardiovascular Mechanisms of Action of DA1 and DA2 Receptor Agonists
7. Correlation of Dopamine Receptor Selectivity and Hemodynamic Effects on
the Intact Animal 8. Peripheral Dopaminergic Agonist Activity of
Aminoethylindolones and Related Compounds 9. Cardiovascular Activity of
Ergoline Derivatives 10. Inhibition of Dopamine ß-Hydroxylase to Increase
Dopaminergic Tone In Vivo Part IV: Dopamine Receptors in Man: Therapeutic
Applications 11. Clinical Utility of Cardiovascular Agents Acting on the
Dopamine Receptor 12. Dopaminergic Control of Aldosterone Secretion 13.
Hemodynamic Activity of N-n -propyl-N-n -Butyldopamine 14. Clinical Effects
of Fenoldopam, a Potent Dopamine (DA1) Agonist